Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026. Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs On December 30, Barclays raised its price target on Johnson & Johnson (NYSE:JNJ) to $217 from$197 and kept an Equal Weight rating on the shares. The firm reviewed sales and prescription data through the final week of December and sees room for upside to Q4 consensus estimates. The strength is coming mainly from Darzalex, Tremfy ...